Trials / Completed
CompletedNCT02410135
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 34 (actual)
- Sponsor
- Southern Illinois University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this exploratory pilot study is to assess whether Mirabegron (Myrbetriq™) will improve the quality of sleep and Lower Urinary Tract Symptoms (LUTS) in men and women presenting with LUTS and disordered sleep.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirabegron | 25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2015-04-07
- Last updated
- 2019-05-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02410135. Inclusion in this directory is not an endorsement.